Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
|
|
Gay City News (New York) (04.27.06) - Friday, May 05, 2006
Duncan Osborne
"The studies that have been done so far have been done in animals and are based on theoretical models," said Richard Jeffries, director of basic science, prevention, and vaccines at Treatment Action Group (TAG), a forum sponsor. "Obviously, the big question is what will happen in people? What kind of toxicities will we see?"
One US study is enrolling 400 gay or bisexual men in Atlanta and San Francisco for a 24-month controlled safety and efficacy trial of tenofovir for PrEP. It will also monitor for adherence issues and any sexual risk changes.
"We're not talking about the evening before or the morning after," said Dr. Albert Liu, director of HIV Prevention Studies at San Francisco's Department of Public Health, a study site. "We're talking about a continuous dose."
In Peru, a controlled trial enrolling 1,400 gay or bisexual men will test truvada (tenofovir and FTC) PrEP for 20 months. In Thailand, Ghana, and Botswana, 3,200 men and women will test the PrEP efficacy of either truvada or tenofovir.
Last year, at least six mainstream press articles discussed the fact that some gay men are already using HIV drugs for PrEP. A 2005 CDC survey of San Francisco gay men found that 7 percent reported using drugs for PrEP "at some point in the past," said J. Jeff McConnell, a co-investigator of the Peru study.
"We're definitely not a cheerleader for PrEP," clarified panel member Raffi Babakhanian of the Community HIV/AIDS Mobilization Project (CHAMP), the forum's primary sponsor. "I don't think we're at a point where anybody can be a cheerleader." "There isn't a clear corollary" to PrEP, said Edd Lee, director of community education and outreach at the AIDS Vaccine Advocacy Coalition, which also sponsored. "That's why this research is so new."
060505
AD060804
Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.